The approval of Prevenar 13 was based on the review of clinical immunogenicity and safety data involving more than 6,000 adults aged 50 years and older.
Prevenar 13 uses company-pioneered conjugation technology and prevents invasive pneumococcal disease caused by the 13 serotypes contained in the vaccine and is for a single dose.